Myeloproliferative Neoplasms (MPN) Overview

Save information for later
Sign Up

Learn About Myeloproliferative Neoplasms (MPN)

What is the definition of Myeloproliferative Neoplasms (MPN)?
Myeloproliferative neoplasms are rare blood cancers caused by the body making too many red blood cells, white blood cells, or platelets. There are several types of myeloproliferative neoplasms, including chronic myelogenous leukemia, polycythemia vera, primary myelofibrosis, essential thrombocythemia, chronic neutrophilic leukemia, and chronic eosinophilic leukemia.
What are the symptoms of Myeloproliferative Neoplasms (MPN)?
Symptoms of myeloproliferative neoplasms may not appear for years. Symptoms of myeloproliferative neoplasms depend on the type. The most common symptom is discomfort or pressure on the left side below the ribs due to an enlarged spleen. Other symptoms may include bone pain; night sweats; fever; fatigue; bruising easily; loss of appetite; unexplained weight loss; unexplained bleeding; blood in the urine; headaches; dizziness; blurred or double vision; pale or itchy skin; abdominal fullness; reddened face; weakness; shortness of breath; hearing problems; cough; swelling of the face, throat, hands or feet; muscle pain; and diarrhea.
Not sure about your diagnosis?
Check Your Symptoms
What are the different types of Myeloproliferative Neoplasms (MPN)?

Common conditions include: Myelofibrosis

What are the current treatments for Myeloproliferative Neoplasms (MPN)?
There is currently no cure for myeloproliferative neoplasms. Treatment for myeloproliferative neoplasms is focused on relieving the symptoms and preventing complications. Treatments for myeloproliferative neoplasms include watchful waiting, phlebotomy, platelet apheresis, transfusion therapy, chemotherapy, radiation therapy, drug therapy, immunotherapy, targeted therapy, chemotherapy, and stem cell transplant.
Who are the top Myeloproliferative Neoplasms (MPN) Local Doctors?
Dr. Elizabeth O. Hexner
Hematology | Oncology
Dr. Elizabeth O. Hexner
Hematology | Oncology

University Of Penn - Medical Group

3400 Civic Ctr Blvd, 
Philadelphia, PA 
 (4.0 mi)
215-615-5858
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Elizabeth Hexner is a Hematologist and an Oncologist in Philadelphia, Pennsylvania. Dr. Hexner and is rated as an Elite provider by MediFind in the treatment of Myeloproliferative Neoplasms (MPN). Her top areas of expertise are Systemic Mastocytosis, Myelofibrosis, Myeloproliferative Neoplasms (MPN), Bone Marrow Transplant, and Bone Marrow Aspiration.

Dr. Michael Rachshtut
Hematology Oncology | Oncology | Hematology
Dr. Michael Rachshtut
Hematology Oncology | Oncology | Hematology

Cmc Dept Of Medicine Group PA

2 Cooper Plz, 
Camden, NJ 
 (0.1 mi)
855-632-2667
Languages Spoken:
English
See accepted insurances

Michael Rachshtut is a Hematologist Oncology specialist and an Oncologist in Camden, New Jersey. Dr. Rachshtut and is rated as an Experienced provider by MediFind in the treatment of Myeloproliferative Neoplasms (MPN). His top areas of expertise are Iron Deficiency Anemia, Childhood Iron Deficiency Anemia, Ovarian Carcinosarcoma, and Testicular Yolk Sac Tumor.

 
 
 
 
Learn about our expert tiers
Learn More
Dr. Henry H. Fung
Hematology Oncology | Hematology | Oncology
Dr. Henry H. Fung
Hematology Oncology | Hematology | Oncology

Temple Faculty Practice Plan Inc

3401 N Broad St, 
Philadelphia, PA 
 (4.7 mi)
215-707-5030
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Henry Fung is a Hematologist Oncology specialist and a Hematologist in Philadelphia, Pennsylvania. Dr. Fung and is rated as an Experienced provider by MediFind in the treatment of Myeloproliferative Neoplasms (MPN). His top areas of expertise are Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

View All Doctors
What are the latest Myeloproliferative Neoplasms (MPN) Clinical Trials?
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms
Enrollment Status: Recruiting
Publish Date: January 10, 2025
Intervention Type: Drug
Study Phase: Phase 1

Summary: The purpose of this study is to characterize safety and to determine the Recommended Phase 2 Dose (RP2D\[s\]) and optimal dosing schedule(s) of JNJ-88549968, in part 1 (Dose Escalation); to characterize the safety of JNJ- 88549968 at RP2D(s), in part 2 (Cohort Expansion).

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 1, Open-Label, Multicenter Study of INCB160058 in Participants With Myeloproliferative Neoplasms
A Phase 1, Open-Label, Multicenter Study of INCB160058 in Participants With Myeloproliferative Neoplasms
Enrollment Status: Recruiting
Publish Date: December 30, 2024
Intervention Type: Drug
Study Phase: Phase 1

Summary: This study is being conducted to assess the Safety, Tolerability, and Pharmacokinetics of INCB160058 in Participants With Myeloproliferative Neoplasms.

View All Clinical Trials